M
Mary Ann Melnick
Researcher at Yale University
Publications - 16
Citations - 1447
Mary Ann Melnick is an academic researcher from Yale University. The author has contributed to research in topics: Lung cancer & Cetuximab. The author has an hindex of 7, co-authored 13 publications receiving 1120 citations.
Papers
More filters
Journal ArticleDOI
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
Ken Takezawa,Valentina Pirazzoli,Maria E. Arcila,Caroline A. Nebhan,Xiaoling Song,Elisa de Stanchina,Kadoaki Ohashi,Yelena Y. Janjigian,Paula J. Spitzler,Mary Ann Melnick,G. J. Riely,Mark G. Kris,Vincent A. Miller,Marc Ladanyi,Katerina Politi,William Pao +15 more
TL;DR: It is shown in vitro and in vivo that afatinib plus cetuximab significantly inhibits HER2 phosphorylation, and this results reveal a previously unrecognized mechanism of resistance to EGFR-TKIs and provide a rationale to assess the status and possibly target HER2 in EG FR-mutant tumors with acquired resistance toEGFR- TKIs.
Journal ArticleDOI
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
Scott N. Gettinger,Jungmin Choi,Katherine Hastings,Anna Truini,Ila Datar,Ryan T. Sowell,Anna Wurtz,Weilai Dong,Guoping Cai,Mary Ann Melnick,Victor Y. Du,Joseph Schlessinger,Sarah B. Goldberg,Anne C. Chiang,Miguel F. Sanmamed,Ignacio Melero,Jackeline Agorreta,Luis M. Montuenga,Richard P. Lifton,Soldano Ferrone,Paula B. Kavathas,David L. Rimm,Susan M. Kaech,Kurt A. Schalper,Roy S. Herbst,Katerina Politi +25 more
TL;DR: CRISPR-mediated knockout of B2m in an immunocompetent lung cancer mouse model conferred resistance to PD-1 blockade in vivo, proving its role in resistance to ICIs.
Journal ArticleDOI
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer
Elza C. de Bruin,Catherine F. Cowell,Patricia H. Warne,Ming Jiang,Rebecca E. Saunders,Mary Ann Melnick,Scott N. Gettinger,Zenta Walther,Anna Wurtz,Guus J. J. E. Heynen,Daniëlle A.M. Heideman,Jose Javier Gomez-Roman,Almudena García-Castaño,Yixuan Gong,Marc Ladanyi,Harold E. Varmus,René Bernards,Egbert F. Smit,Katerina Politi,Julian Downward +19 more
TL;DR: A subgroup of patients with EG FR-mutant lung adenocarcinoma who might benefit from combination therapy with EGFR and MEK inhibitors are identified.
Journal ArticleDOI
miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma
Wen Cai Zhang,Julie Wells,Kin-Hoe Chow,He Huang,Min Yuan,Tanvi Saxena,Mary Ann Melnick,Katerina Politi,John M. Asara,Daniel B. Costa,Carol J. Bult,Frank J. Slack +11 more
TL;DR: Tolerance to the EGFR inhibitor osimertinib in non-small-cell lung cancer is mediated by the effects of miR-147b on the tricarboxylic acid cycle and pseudohypoxia pathways, which can be manipulated with a miR -147b inhibitor.
Journal ArticleDOI
Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells
Matteo Forloni,Romi Gupta,Arvindhan Nagarajan,Lisha Sun,Yuying Dong,Valentina Pirazzoli,Maria I. Toki,Anna Wurtz,Mary Ann Melnick,Susumu Kobayashi,Robert J. Homer,David L. Rimm,Scott J. Gettinger,Katerina Politi,Shaillay Kumar Dogra,Narendra Wajapeyee +15 more
TL;DR: It is shown that oncogenic epidermal growth factor receptor (EGFR) induces silencing of multiple unrelated tumor suppressors in lung adenocarcinomas and glioblastomas by inhibiting the DNA demethylase TET oncogene family member 1 (TET1) via the C/EBPα transcription factor.